DPYD and breast cancer: Although DPYD mRNA expression did not show a significant prognostic role in BC patients (Supplementary Fig. 5A, B), analysis of expression data from the CCLE showed a marked increase in mesenchymal-like BC cells not only for DPYD, but also for the NT5E (CD73), which is one of the upstream 5′-nucleotidase responsible for catalyzing the first step of dTMP degradation (Fig. 7b).